Simon Peter Gampenrieder

7PUBLICATIONS
16CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Bioinformatic methods developmentGene and molecular therapyBiomechanics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 29, 2026
Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samples.

Franz Josef Gassner, Gabriel Rinnerthaler, Vanessa Castagnaviz

|Oct 22, 2025
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis.

Dora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter

|Apr 01, 2025
A comparison of breast cancer incidence and cancer stages before and after the introduction of the Austrian national breast cancer screening program in the federal state of Salzburg : Real-world data from the Tumor Registry Salzburg.

Simon Peter Gampenrieder, Marc Vaisband, Gabriel Rinnerthaler

|Dec 04, 2021
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Qing Zhou, Simon P Gampenrieder, Sophie Frantal

|Oct 25, 2021
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).

Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer

|Jun 05, 2020
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.

Gabriel Rinnerthaler, Simon Peter Gampenrieder, Hubert Hackl

Pageof 2

Frequent Collaborators

2 joint publications

Richard Greil

1 joint publications

Qing Zhou

1 joint publications

Gabriel Rinnerthaler

1 joint publications

Daniel Egle